JFJia-Long Fang

Jia-Long Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jia-Long Fang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Frederick A. Beland

    Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA

    15 shared publications
  • Frederick A. Beland

    Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, USA

    8 shared publications
  • Yuanfeng Wu

    Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), U.S Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, 72079, USA

    7 shared publications
  • Gonçalo Gamboa da Costa

    Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079, U.S.A.

    5 shared publications
  • Si Chen

    Division of Biochemical Toxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, USA

    5 shared publications
  • Greg R. Olson

    Toxicologic Pathology Associates, Inc., National Center for Toxicological Research, Jefferson, USA

    4 shared publications

Latest Publications

  • Open Access

    Contribution of cytochrome P450-mediated metabolism to clavulanic acid-induced cytotoxicity in TK6-derived cytochrome P450-overexpressing cell lines

    by Jia-Long Fang, Xilin Li, Si Chen, Frederick A. Beland

    Clavulanic acid, a β-lactamase inhibitor, is widely co-administered with amoxicillin (as in Augmentin ) to treat a broad range of mild-to-moderate bacterial infections by inhibiting β-lactamase enzymes produced by resistant bacterial strains. Despite its therapeutic efficacy, clavulanic acid has been associated with drug-induced liver injury, but the underlying mechanisms for this toxicity remain poorly understood. We investigated the contribution of cytochrome P450 (CYP)-mediated metabolism in relation to clavulanic acid-induced cytotoxicity. A panel of TK6-derived cell lines overexpressing 18 individual CYP isoforms (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) was employed. Cells were incubated for 24 and 48 h with freshly prepared clavulanic acid (20-1000 µM) in RPMI-1640 medium, and the half-maximal inhibitory concentration (IC₅₀) was determined. Cell growth was more markedly delayed after 48 h of treatment than after 24 h of exposure. Following 48 h of treatment, 13 CYP-overexpressing cell lines showed reduced IC₅₀ values compared with parental TK6 and TK6/vector control cells. The rank order was CYP3A4 ≈ CYP3A7 ≈ CYP1A1 < CYP4A11 ≈ CYP2A13 ≈ CYP2C19 < CYP2B6 ≈ CYP1A2 ≈ CYP2C9 < CYP1B1 ≈ CYP2D6 < CYP2E1 ≈ CYP2C18, with the greatest decrease (~2-fold) observed in TK6/CYP3A4 cells. In contrast, five isoforms (CYP2A6, CYP2A7, CYP2C8, CYP3A5, and CYP4B1) showed IC₅₀ values comparable to controls. To examine further the cytotoxic response, TK6/CYP vector and TK6/CYP3A4 cells were treated for 48 h with equitoxic concentrations of clavulanic acid (0.1×, 0.5×, and 1.0× IC₅₀). The exposures resulted in a significant concentration-dependent reduction in cell viability, accompanied by increased lactate dehydrogenase release, the induction of apoptosis, G₀/G₁ phase arrest, and a concentration-dependent elevation in γH2AX phosphorylation, indicative of DNA damage. In conclusion, CYP enzymes, especially CYP3A4, likely contribute to clavulanate-induced cytotoxicity, with necrosis, cell cycle disruption, and γH2AX-associated apoptosis as key cellular responses.

  • Open Access

    Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma

    by Jia-Long Fang, Leeza Shrestha, Frederick A. Beland

    COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Anti-SARS-CoV-2 antibodies can provide information on patient immunity, identify asymptomatic patients, and track the spread of COVID-19. Efforts have been made to develop methods to detect anti-SARS-CoV-2 antibodies in humans. Here, we describe a flow cytometric assay for the simultaneous detection of anti-SARS-CoV-2 IgG and IgM in human plasma. To assess the antibody response against the different SARS-CoV-2 structural proteins, five viral recombinant proteins, including spike protein subunit 1 (S1), N-terminal domain of S1 (S1A), spike receptor-binding domain (RBD), spike protein subunit 2 (S2), and nucleocapsid protein (N), were generated. A comparison of the antibody profiles detected by the assay with plasma from 100 healthy blood donors collected prior to the COVID-19 pandemic and plasma from 100 virologically confirmed COVID-19 patients demonstrated a clear discrimination between the two groups. Among the COVID-19 patients, the antibody responses for the viral proteins, as determined by their prevalence, were anti-RBD IgG = anti-N IgG > anti-S1 IgG > anti-S1A IgG > anti-S2 IgG, and anti-RBD IgM > anti-S1 IgM > anti-N IgM > anti-S2 IgM. The prevalence of anti-SARS-CoV-2 IgG and IgM was not associated with sex, age, race, days after the onset of symptoms, or severity of illness, except for a higher prevalence of anti-S2 IgG being observed in men than in women. The levels of anti-RBD IgG were higher in patients 65 years and older and in patients who had severe symptoms. Similarly, patients who had severe symptoms exhibited higher levels of anti-S1 and anti-S1A IgG than patients who had mild or moderate symptoms. The levels of anti-RBD IgM tended to be higher in men but did not differ among age, race, days after the onset of symptoms, or severity of illness. Our study indicates that the flow cytometric assay, especially using RBD as target antigen, can be used to detect simultaneously anti-SARS-CoV-2 IgG and IgM antibodies in human plasma.

  • Two-year dermal carcinogenicity bioassay of triclosan in B6C3F1 mice

    by Jia-Long Fang, Michelle M. Vanlandingham, Greg R. Olson, Mackean P. Maisha, Robert Felton, Frederick A. Beland

    Triclosan is a widely used antimicrobial agent in personal care products, household items, medical devices, and clinical settings. Due to its extensive use, there is potential for humans in all age groups to receive lifetime exposures to triclosan, yet data on the chronic dermal toxicity/carcinogenicity of triclosan are still lacking. We evaluated the toxicity/carcinogenicity of triclosan administered dermally to B6C3F1 mice for 104 weeks. Groups of 48 male and 48 female B6C3F1 mice received dermal applications of 0, 1.25, 2.7, 5.8, or 12.5 mg triclosan/kg body weight (bw)/day in 95% ethanol, 7 days/week for 104 weeks. Vehicle control animals received 95% ethanol only; untreated, naïve control mice did not receive any treatment. There were no significant differences in survival among the groups. The highest dose of triclosan significantly decreased the body weight of mice in both sexes, but the decrease was ≤ 9%. Minimal-to-mild epidermal hyperplasia, suppurative inflammation (males only), and ulceration (males only) were observed at the application site in the treated groups, with the highest incidence occurring in the 12.5 mg triclosan/kg bw/day group. No tumors were identified at the application site. Female mice had a positive trend in the incidence of pancreatic islet adenoma. In male mice, there were positive trends in the incidences of hepatocellular carcinoma and hepatocellular adenoma or carcinoma (combined), with the increase of carcinoma being significant in the 5.8 and 12.5 mg/kg/day groups and the increase in hepatocellular adenoma or carcinoma (combined) being significant in the 2.7, 5.8, and 12.5 mg/kg/day groups.


  • Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats

    by Jia-Long Fang, Michelle M. Vanlandingham, Frederick A. Beland, Robert P. Felton, Mackean P. Maisha, Greg R. Olson, Ralph E. Patton, Amy S. Rosenberg, Gonçalo Gamboa da Costa


  • Open Access

    Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma

    by Jia-Long Fang, Frederick A. Beland, Yangshun Tang, Steve R. Roffler


  • Role of peroxisome proliferator-activated receptor alpha (PPARα) and PPARα-mediated species differences in triclosan-induced liver toxicity

    by Yangshun Tang, Michelle M. Vanlandingham, Yuanfeng Wu, Frederick A. Beland, Greg R. Olson, Jia-Long Fang

    Triclosan, a widely used broad spectrum anti-bacterial agent, is hepatotoxic in rodents and exhibits differential effects on mouse and human peroxisome proliferator-activated receptor alpha (PPARα) in vitro; however, the mechanism underlying triclosan-induced liver toxicity has not been elucidated. This study examined the role of mouse and human PPARα in triclosan-induced liver toxicity by comparing the effects between wild-type and PPARα-humanized mice. Female mice of each genotype received dermal applications of 0, 58, or 125 mg triclosan/kg body weight daily for 13 weeks. Following the treatment, triclosan caused an increase in liver weight and relative liver weight only in wild-type mice. The expression levels of PPARα target genes cytochrome P450 4A and acyl-coenzyme A oxidase 1 were increased in livers of both wild-type and PPARα-humanized mice, indicating that triclosan activated PPARα. Triclosan also elevated the expression levels of peroxisomal membrane protein PMP70 and catalase in the livers of both genotypes, suggesting that triclosan promoted the production of hepatocyte peroxisomes. There was an enhanced expression of cyclin D1, c-myc, proliferating cell nuclear antigen, and Ki67, and a higher percentage of BrdU-labeled hepatocytes in wild-type mice, but not in PPARα-humanized mice, demonstrating triclosan-activated PPARα had differential effects on the hepatocyte proliferation. These findings imply that the differential effects of triclosan-activated PPARα on cell proliferation may play a role in the species differences in triclosan-induced liver toxicity.


  • Effects of human sulfotransferases on the cytotoxicity of 12-hydroxynevirapine

    by Jia-Long Fang, Lucie Loukotková, Priyanka Chitranshi, Gonçalo Gamboa da Costa, Frederick A. Beland


  • Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells

    by Yuanfeng Wu, Priyanka Chitranshi, Lucie Loukotková, Gonçalo Gamboa da Costa, Frederick A. Beland, Jie Zhang, Jia-Long Fang

    Triclosan is a widely used broad-spectrum anti-bacterial agent. The objectives of this study were to identify which cytochrome P450 (CYP) isoforms metabolize triclosan and to examine the effects of CYP-mediated metabolism on triclosan-induced cytotoxicity. A panel of HepG2-derived cell lines was established, each of which overexpressed a single CYP isoform, including CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1. The extent of triclosan metabolism by each CYP was assessed by reversed-phase high-performance liquid chromatography with online radiochemical detection. Seven isoforms were capable of metabolizing triclosan, with the order of activity being CYP1A2 > CYP2B6 > CYP2C19 > CYP2D6 ≈ CYP1B1 > CYP2C18 ≈ CYP1A1. The remaining 11 isoforms (CYP2A6, CYP2A7, CYP2A13, CYP2C8, CYP2C9, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, and CYP4B1) had little or no activity toward triclosan. Three metabolites were detected: 2,4-dichlorophenol, 4-chlorocatechol, and 5′-hydroxytriclosan. Consistent with the in vitro screening data, triclosan was extensively metabolized in HepG2 cells overexpressing CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP2C18, and these cells were much more resistant to triclosan-induced cytotoxicity compared to vector cells, suggesting that CYP-mediated metabolism of triclosan attenuated its cytotoxicity. In addition, 2,4-dichlorophenol and 4-chlorocatechol were less toxic than triclosan to HepG2/vector cells. Conjugation of triclosan, catalyzed by human glucuronosyltransferases (UGTs) and sulfotransferases (SULTs), also occurred in HepG2/CYP-overexpressing cells and primary human hepatocytes, with a greater extent of conjugation being associated with higher cell viability. Co-administration of triclosan with UGT or SULT inhibitors led to greater cytotoxicity in HepG2 cells and primary human hepatocytes, indicating that glucuronidation and sulfonation of triclosan are detoxification pathways. Among the 18 CYP-overexpressing cell lines, an inverse correlation was observed between cell viability and the level of triclosan in the culture medium. In conclusion, human CYP isoforms that metabolize triclosan were identified, and the metabolism of triclosan by CYPs, UGTs, and SULTs decreased its cytotoxicity in hepatic cells.